PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcmedicineBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Medicine
 
BMC Med. 2012; 10: 12.
Published online 2012 February 2. doi:  10.1186/1741-7015-10-12
PMCID: PMC3286370
Treatment of enterohemorrhagic Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS)
Paul N Goldwatercorresponding author1 and Karl A Bettelheim2
1Microbiology and Infectious Diseases, SA Pathology at the Women's and Children's Hospital, and Discipline of Paediatrics, University of Adelaide, 72 King William Road, North Adelaide, South Australia, Australia
2K.A.B.: Flat 5, Rosedale Lodge, 220 Chase Side, Southgate, London, N14 4PM, UK
corresponding authorCorresponding author.
Paul N Goldwater: paul.goldwater/at/health.sa.gov.au; Karl A Bettelheim: bettelheim/at/talktalk.net
Received August 16, 2011; Accepted February 2, 2012.
Abstract
Verotoxigenic Escherichia coli (VTEC) are a specialized group of E. coli that can cause severe colonic disease and renal failure. Their pathogenicity derives from virulence factors that enable the bacteria to colonize the colon and deliver extremely powerful toxins known as verotoxins (VT) or Shiga toxins (Stx) to the systemic circulation. The recent devastating E. coli O104:H4 epidemic in Europe has shown how helpless medical professionals are in terms of offering effective therapies. By examining the sources and distribution of these bacteria, and how they cause disease, we will be in a better position to prevent and treat the inevitable future cases of sporadic disease and victims of common source outbreaks. Due to the complexity of pathogenesis, it is likely a multitargeted approach is warranted. Developments in terms of these treatments are discussed.
Keywords: enterohemorrhagic Escherichia coli (EHEC), verotoxigenic (VTEC) hemolytic uremic syndrome (HUS), treatment, pathogenicity, EAHEC
Articles from BMC Medicine are provided here courtesy of
BioMed Central